Quick Answer
Spyre Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Spyre Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $0.00 | Fiscal year 2023: $886.0 thousand | Fiscal year 2022: $2.33 million | Fiscal year 2021: $18.74 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $0.00 | Fiscal year 2018: $3.89 million | Fiscal year 2017: $5.21 million | Fiscal year 2016: $4.63 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: